Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial
- 1Division of Molecular Epidemiology, Jikei University School of Medicine, Tokyo 105-8461, Japan
- 2Department of Surgery, International University of Health and Welfare Hospital,Tochigi 329-2763, Japan
Abstract
Background: Accumulating evidence suggests that vitamin D may influence cancer prognosis. We aimed to explore whether the TP53 codon 72 polymorphism (p.Pro72Arg; rs1042522) may be associated with differential effects of vitamin D supplementation on digestive tract cancer prognosis. Methods: This post hoc analysis of the AMATERASU randomized controlled trial included patients in whom both germline TP53 codon 72 genotype and p53 immunohistochemistry (IHC) assessment were available. Patients were stratified according to TP53 codon 72 genotype and p53 IHC expression. The association between vitamin D supplementation and relapse-free survival (RFS) was evaluated using Cox proportional hazards regression models within each subgroup. Results: A total of 333 participants (79.9%) out of 417 in the AMATERASU trial were included in the analysis. RFS was comparable between the vitamin D and placebo groups across the TP53 codon 72 genotype subgroups. The vitamin D group was significantly associated with more favorable RFS compared with the placebo group in patients with both the Arg/Arg genotype and high p53 IHC expression (HR, 0.32; 95% CI, 0.12–0.87; p = 0.03). However, with a fragility index of 2 and a non-significant three-way interaction among vitamin D supplementation, p53 IHC expression, and the Arg/Arg genotype (p for interaction = 0.09), these findings remain fragile despite reaching statistical significance, warranting careful interpretation. Conclusions: Vitamin D supplementation was associated with more favorable RFS among patients with digestive tract cancer who had both the Arg/Arg genotype and high p53 IHC expression. These exploratory findings warrant further investigation in prospective studies.
Related
- Vitamin D Receptor Genotype, Tumor Expression, and Outcomes After Vitamin D Supplementation in Digestive Tract Cancer: An Exploratory Post Hoc Analysis of the AMATERASU Trial
- Association of Plasma CCDC88A Expression Combined with Erythrocyte Sedimentation Rate with Rheumatoid Arthritis Disease Activity: A Cross-Sectional Exploratory Study.
- Combined plasma and liquid-based cytology microRNA signatures as biomarkers of high-grade cervical lesions: association with HPV infection and p16 expression.
- Association of Haptoglobin Genotype with Cardiovascular Disease and Left Ventricular Ejection Fraction in Kidney Transplant Recipients
- OX40/OX40L signaling pathway gene variants and preeclampsia risk: a case-control study with combined genotype analysis.
BibTeX
@article{fukuzato2026combined,
title = {{Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial}},
author = {Soichiro Fukuzato and Taisuke Akutsu and Hironori Ohdaira and Yutaka Suzuki and Mitsuyoshi Urashima},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203286},
url = {https://www.mdpi.com/2072-6694/18/20/3286},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Combined TP53 Codon 72 Genotype and p53 Expression in Association with Vitamin D Benefit in Digestive Tract Cancer: A Post-Hoc Study of the AMATERASU Trial
AU - Soichiro Fukuzato
AU - Taisuke Akutsu
AU - Hironori Ohdaira
AU - Yutaka Suzuki
AU - Mitsuyoshi Urashima
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203286
UR - https://www.mdpi.com/2072-6694/18/20/3286
AB - Background: Accumulating evidence suggests that vitamin D may influence cancer prognosis. We aimed to explore whether the TP53 codon 72 polymorphism (p.Pro72Arg; rs1042522) may be associated with differential effects of vitamin D supplementation on digestive tract cancer prognosis. Methods: This post hoc analysis of the AMATERASU randomized controlled trial included patients in whom both germline TP53 codon 72 genotype and p53 immunohistochemistry (IHC) assessment were available. Patients were stratified according to TP53 codon 72 genotype and p53 IHC expression. The association between vitamin D supplementation and relapse-free survival (RFS) was evaluated using Cox proportional hazards regression models within each subgroup. Results: A total of 333 participants (79.9%) out of 417 in the AMATERASU trial were included in the analysis. RFS was comparable between the vitamin D and placebo groups across the TP53 codon 72 genotype subgroups. The vitamin D group was significantly associated with more favorable RFS compared with the placebo group in patients with both the Arg/Arg genotype and high p53 IHC expression (HR, 0.32; 95% CI, 0.12–0.87; p = 0.03). However, with a fragility index of 2 and a non-significant three-way interaction among vitamin D supplementation, p53 IHC expression, and the Arg/Arg genotype (p for interaction = 0.09), these findings remain fragile despite reaching statistical significance, warranting careful interpretation. Conclusions: Vitamin D supplementation was associated with more favorable RFS among patients with digestive tract cancer who had both the Arg/Arg genotype and high p53 IHC expression. These exploratory findings warrant further investigation in prospective studies.
SN - 2072-6694
ER -